-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Tobacco Control Impacts Everyone in Respiratory Medicine, JTO CRR Editor Says
In a Q&A with ILCN, new JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone discusses her passion for tobacco control and the importance of open-access journals in elevating research globally.
-
Patient Perspective: ‘Scanxiety’ Triggered by Cancer, Not Scans
Patient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning.
-
TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies
During the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research.
-
Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations
During TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression.
-
Scenes from TTLC 2023
Revisit all your favorite moments from #TTLC23 in our photo gallery.
-
CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says
In a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC.
-
Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?
Study highlights limitations of relying solely on clinical smoking history, and findings suggest tobacco smoking-related mutational signatures could potentially guide molecular testing and optimize patient stratification in clinical trials.
-
TTLC 2023 Showcases Early Ongoing Trial Data, Newest Therapies
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN.
-
Patient Perspective: Me, Myself, and Scanxiety
Studies that don’t show survival benefit with more frequent surveillance won’t convince patients they’re better off without scans. Even if regularly scheduled scans don’t help patients live longer, they do help them live better.
-
In Brief for Feb. 22, 2023
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership.
View ILCN Archives
Provider Resources
Popular Articles